September 18, 2020
Kyowa Kirin has seen a steady switch from its flagship renal anemia treatment Nesp (darbepoetin alfa) to its so-called “biosame” version rolled out last summer, but biosimilar contenders are also faring strongly, President Masashi Miyamoto said at a virtual press...read more